DAYTON — Solvita has acquired the assets of Snoasis Medical LLC to bring the BioXclude® product and brand exclusively into the Maxxeus portfolio.

BioXclude, known for its superior quality and performance in regenerative medicine, said a Solvita press release, has been the leading amnion-chorion membrane used in dental procedures. Solvita has been manufacturing the BioXclude product and the acquisition by Solvita ensures that the same high standards will be maintained, and customers can continue to expect the exceptional product they have relied on.

“We are thrilled to have BioXclude in our portfolio and to offer it exclusively through our Maxxeus brand,” said Tom Shaffer, chief commercial officer at Solvita, in the release. “BioXclude is a wonderful product with years of science and clinical outcomes studies that support its superior performance. By adding BioXclude exclusively to our Maxxeus dental business, many more clinicians will be able to experience the benefits of this product firsthand through our expansive sales and marketing channels.”

Founder of Snoasis LLC, Rob Tofe said in the release, “We are incredibly grateful to the more than 3,000 doctors who have integrated BioXclude into their practices, helping to advance dental surgery with the use of placental allografts. We are excited for this new chapter with Solvita and confident that BioXclude will continue to thrive under their leadership.”

For more information about BioXclude and the transition to Maxxeus, please contact their customer service team at 855-629-9387.